{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:37Z","timestamp":1790401777135,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"DOI":"10.3389\/fcvm.2019.00003","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T04:53:36Z","timestamp":1548219216000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":86,"title":["Cardiac Complications in Immune Checkpoint Inhibition Therapy"],"prefix":"10.3389","volume":"6","author":[{"given":"Kazuko","family":"Tajiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (Anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors\u2014an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e003514","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung","volume":"99","author":"Semper","year":"2016","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"bcr2016216228","DOI":"10.1136\/bcr-2016-216228","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","volume":"2016","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","article-title":"Confusing signals: recent progress in CTLA-4 biology","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J Leukoc Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.autrev.2013.05.003","article-title":"Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity","volume":"12","author":"Gianchecchi","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci USA."},{"key":"B26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2263-4","article-title":"Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment","author":"Umezu","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1327494","DOI":"10.1080\/2162402X.2017.1327494","article-title":"PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11912-018-0718-6","article-title":"Immune checkpoint inhibitor toxicity","volume":"20","author":"Palmieri","year":"2018","journal-title":"Curr Oncol Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.tcm.2012.07.005","article-title":"Role of impaired central tolerance to \u03b1-myosin in inflammatory heart disease","volume":"22","author":"Lv","year":"2012","journal-title":"Trends Cardiovasc Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.icb.7100141","article-title":"What do we know about the mechanisms of elimination of autoreactive T and B cells and what challenges remain","volume":"86","author":"Strasser","year":"2008","journal-title":"Immunol Cell Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ni.1817","article-title":"Mechanisms maintaining peripheral tolerance","volume":"11","author":"Mueller","year":"2010","journal-title":"Nat Immunol."},{"key":"B39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jjco\/hyx154","article-title":"Immune checkpoint inhibitor-related myocarditis","volume":"48","author":"Tajiri","year":"2018","journal-title":"Jpn J Clin Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor\u2013related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1093\/eurheartj\/ehy485","article-title":"Immune checkpoint inhibitors myocarditis: not all cases are clinically patent","volume":"39","author":"Thibault","year":"2018","journal-title":"Eur Heart J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","article-title":"Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients","volume":"23","author":"Sarocchi","year":"2018","journal-title":"Oncologist"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2019.00003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T04:53:37Z","timestamp":1548219217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcvm.2019.00003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":53,"alternative-id":["10.3389\/fcvm.2019.00003"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2019.00003","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"article-number":"3"}}